Investing.com - INmune Bio (NASDAQ: INMB) reported third quarter EPS of $-0.48, $0.08 worse than the analyst estimate of $-0.40. Revenue for the quarter came in at $43K versus the consensus estimate of $46K.
INmune Bio's stock price closed at $7.07. It is down -17.89% in the last 3 months and down -2.08% in the last 12 months.
INmune Bio saw positive EPS revisions and negative EPS revisions in the last 90 days. See INmune Bio's stock price’s past reactions to earnings here.
According to InvestingPro, INmune Bio's Financial Health score is "fair performance".
Check out INmune Bio's recent earnings performance, and INmune Bio's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar